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Purpose or Objective: At our center, the need for neck 
dissection (ND) after radiotherapy (RT) is determined based 
on the nodal response on the post-RT Computed Tomography 
(CT) study 4 months after the end of treatment. We want to 
report the outcome of this approach and investigate whether 
characteristics on pre- and post- RT CT studies can predict 
the necessity of post-RT ND. 
 
Material and Methods: Between 2002 and 2012, 183 
consecutive patients with lymph node-positive head and neck 
cancer (HNC) were treated with RT or concurrent 
chemoradiotherapy (CRT) without planned ND. CT studies 
pre- and post-treatment were reviewed for lymph node size 
and presence of necrosis, extracapsular spread and 
calcifications. At patient level, data were correlated with 3 
year regional control (RC), metastasis free survival (MFS), 
disease free survival (DFS) and overall survival (OS). At nodal 
level, data were correlated with relapse of the individual 
lymph nodes (LNR). A stepwise selection procedure was 
followed to construct a multivariable prediction model for 
regional relapse (RR) within 3 years. The area under the ROC 
curve (AUC) was determined for the selected model. 
Additionally a bootstrap-corrected AUC value was calculated. 
This AUC value corrects for overoptimism resulting from the 
fact that model construction and model validation were 
performed on the same data set. 
 
Results: The median follow-up was 60 months. 3-year 
outcome rates were as follows: LC of 84%, RC of 80%, MFS of 
74%, DFS of 61%, OS of 63%. Pre-treatment nodal size at 
patient- and nodal level and presence of necrosis at patient 
level were associated with a poorer outcome. This was also 
the case for post-treatment lymph node size and presence of 
necrosis and extracapsular spread (Table 1). Based on our 
results we developed a multivariate model for RR prediction. 
After performing a stepwise selection procedure pre-RT T 
stage (p=0.02), post-RT necrosis (p=0.03) and post-RT largest 
nodal diameter (p=0.01) were included in the model. The 
AUC of this model was 0.78 (95% CI 0.63;0.84); the bootstrap-
corrected AUC was 0.74 (95% CI 0.67; 0.89). The risk for RR 
within 3 years can be calculated using the following formula:  
 
 
 
Conclusion: Characteristics on the post-RT CT study can 
predict the likelihood of residual lymph node disease and 
outcome. Characteristics on the pre-therapy CT study seem 
less useful for this purpose. A CT-based multivariate 
prognostic model based on our findings was developed which 
can aid in predicting RR. 
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Purpose or Objective: With the success of Intensity 
Modulated Radiotherapy (IMRT) techniques in reducing the 
severity of xerostomia in head and neck cancer (HNC) 
patients, efforts should be made to improve swallowing 
dysfunction, which is potentially even more discomforting 
and incapacitating side effect and adversely affects the 
quality of life. This is a clinical dosimetric study to 
investigate the correlation between radiation doses delivered 
to organs at risk for radiation induced swallowing dysfunction 
(SWOARs) and severity of dysphagia following concurrent 
chemoradiotherapy to HNC patients and evaluate various 
factors which assume importance in determining the risk of 
dysphagia/aspiration.  
 
Material and Methods: 60 Head and Neck cancer patients 
(Oropharynx 28, Hypopharynx 12 and Larynx 20) were 
enrolled between May 2013 and June 2014 for this 
prospective longitudinal study after prior approval from the 
hospital ethics and review committee. Patients were treated 
with curative intent by radiotherapy using IMRT and 
concurrent chemotherapy using cisplatin (40 mg/m2) on 
weekly basis. Delineation of SWOARs was done using RTOG 
guidelines and following structures were contoured: superior, 
middle and inferior pharyngeal constrictor, cricopharyngeal 
muscle, esophageal inlet muscle, cervical esophagus, base of 
tongue, supraglottic and glottic larynx. Dysphagia endpoints 
included both patient-reported (EORTC Head and Neck 
Quality of Life instrument and MD Anderson Dysphagia 
Inventory) and observer-rated scores (Common Terminology 
Criteria for Adverse Events- CTCAE v4.0 and RTOG/EORTC 
Late Radiation Morbidity Scoring). Patients were assessed 
weekly during radiation and at 1 month and 3 months after 
completion of treatment. Correlation between dysphagia and 
radiation doses to SWOARs was assessed.  
 
Results: With an increase in the mean dose to the SWOARs, 
the grades of dysphagia also increased. After 3 months of 
completion of treatment, 27% patients had persistent 
dysphagia of grade 3 or grade 4. Significant correlation was 
observed between patient reported dysphagia scores and the 
mean doses to the superior and middle pharyngeal constrictor 
as well as glottic and supraglottic larynx (p<0.05). Observer 
rated dysphagia scores correlated significantly with mean 
superior pharyngeal constrictor dose and not with dose to 
other SWOARs. Two patients of carcinoma hypopharynx 
developed stricture which correlated significantly with dose 
to esophageal inlet muscle.  
 
Conclusion: Radiotherapy plans sparing SWOARs should be 
generated and implemented to prevent the problem of 
dysphagia. The structures whose damage may cause 
dysphagia and aspiration are the pharyngeal constrictors and 
the glottic and supraglottic larynx. Further studies are 
required to evaluate dose constraints to these SWOARs to 
reduce the incidence of radiation induced dysphagia and thus 
further improve the quality of life in HNC patients. 
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Purpose or Objective: Prognostic factors in early stage 
resected oral squamous cell cancers (OSCC) are not well 
understood. The aim of this audit was to identify factors 
influencing recurrence in pT1-2N0M0 patients with a view to 
determine the role and indications for adjuvant radiotherapy 
(adjRT). 
 
Material and Methods: Between Aug 2011 to May 2014, 120 
patients were determined to have pT-2N0M0 disease 
following histopathological examination after primary surgery 
for oral cancer. Primary sites included oral tongue (66, 55%), 
buccal mucosa (31, 26%), gingiva (10, 8%), retromolar trigone 
(9, 7%) and lip (4, 3%). AdjRT was advised to 46 (38%) 
patients on an individual basis in a multidisciplinary meeting, 
determined by the presence of one or a combination of 
known risk factors. Patients with close or positive margins 
always received chemoradiation. AdjRT was delivered with 
3D conformal or intensity modulated techniques to a dose of 
60Gy/30Fr/6weeks to the tumor bed and 54-
60Gy/30Fr/6weeks to the resected but uninvolved nodal 
levels. Disease –related outcomes were calculated, and 
pathological prognostic factors were assessed using univariate 
and multivariate analyses. The impact of adjRT in reducing 
disease recurrence was assessed. 
 
Results: The median age was 55 (25-82) years. The median 
tumor size was 2.2 cm. The median depth of infiltration was 
6mm. The incidence of known pathological prognostic factors 
is listed in Table 1. The median follow up was 23 months (2-
44 months). A total of 13 patients had recurrence (local 8; 
nodal 4, distant 3, including overlapping failures). All 
locoregional failures were within the RT volumes. The 2yr 
and 3 year disease-free-survival (DFS) was 89% and 82% 
respectively. On univariate analysis pT2 tumors, 
lymphovascular invasion (LVI), perineural invasion (PNI) and 
depth of invasion >=5mm were statistically significant 
prognosticators for DFS (Table 1). Primaries of the oral 
tongue showed a trend towards shorter DFS. None of these 
factors were independently prognostic on multivariate 
analysis. A scoring system using the number of risk-factors 
was created. Patients were grouped as Low risk (0-1 factor); 
Intermediate risk (2-3 factors) and High-risk (4-7 factors). 
There was significant difference in DFS of patients in 
different risk groups (Fig 1). RT was considered unnecessary 
in Low risk patients (none of 39 received RT, 3 yr DFS 97.1%). 
In High risk patients, prognosis was poor despite RT (22/25 
received RT, 3 yr DFS 68.5%). In the Intermediate risk group, 
24/54 patients received RT, but this made no difference to 
the risk of disease recurrence (2 local failures each in RT vs. 
no RT cohorts, 3 yr DFS 85.1% vs 72.1%, p=0.75). 
 
 
 
 
 
 
Conclusion: Several pathological risk factors alone and in 
combination impact disease related outcomes even in pT1-
2N0 OSCC. Standard AdjRT did not have a clear effect on 
reducing recurrence in our cohort in patients with up to 3 risk 
factors. 
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Purpose or Objective: To investigate clinical and volumetric 
prognostic factors in head and neck cancer (HNC) patients 
(pts) treated with curative external beam radiation therapy 
(EBRT). 
 
Material and Methods: Sixty-four oropharyngeal squamous 
cell carcinoma (OSCC) pts and 79 hypopharyngeal squamous 
cell carcinoma (HSCC) pts treated with curative EBRT were 
enrolled in this retrospective analysis. No pt had previously 
undergone surgery for HNC. The median total EBRT dose was 
70 Gy (range, 60–72 Gy). For planning EBRT, computed 
tomography (CT) images were acquired prior to EBRT 
initiation and at 3–5 weeks after the initiation of EBRT for 
replanning in each pt. We assessed the gross tumor volume 
(GTV) reduction rate (GTVRR) on the basis of the results from 
the initial and replanning CT images. Initial cervical body 
volume (CBV) was measured from the initial CT images. For 
induction chemotherapy (IC), seven pts received docetaxel 
(DOC), cisplatin (CDDP), and 5-fluorouracil (5-FU) (TPF 
regimen). One course of CDDP plus 5-FU and two courses of 
TPF regimen were delivered to one pt. In total, 125 pts 
(87.4%) received concurrent chemotherapy (CC) using the 
following regimen: TPF in 55 (38.5%) pts; another CDDP-based 
regimen in 43 (30.1%) pts; another DOC-based regimen in 22 
(15.4%) pts; cetuximab in 3 (2.0%) pts; nedaplatin and 5-FU in 
1 (0.7%) pt; and S-1 (tegafur, gimeracil, and oteracil) in 1 
(0.7%) pt. The disease stage was I in 5 (3.5%) pts, II in 20 
(14%) pts, III in 24 (16.8%) pts, and IV in 93 (65%) pts. 
